Picture of Aptose Biosciences logo

APS Aptose Biosciences Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-10.43%
3m-42.09%
6m-62.16%
1yr+122.12%
Volume Change (%)
10d/3m-36.95%
Price vs... (%)
52w High-82.69%
50d MA-12.79%
200d MA-50.7%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-7308.98%
Return on Equity-361.05%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Aptose Biosciences EPS forecast chart

Profile Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
November 1st, 2006
Public Since
June 4th, 1993
No. of Shareholders
30
No. of Employees
35
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
16,309,393

APS Share Price Performance

Upcoming Events for APS

Aptose Biosciences Inc Annual Shareholders Meeting

Aptose Biosciences Inc Extraordinary Shareholders Meeting

Aptose Biosciences Inc Annual Shareholders Meeting

Q2 2024 Aptose Biosciences Inc Earnings Release

Q3 2024 Aptose Biosciences Inc Earnings Release

Similar to APS

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Antibe Therapeutics(Pre-Merger) logo

Antibe Therapeutics(Pre-Merger)

ca flag iconToronto Stock Exchange

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of Briacell Therapeutics logo

Briacell Therapeutics

ca flag iconToronto Stock Exchange

FAQ